According to Berenberg’s analysis, last year Novo Nordisk and Eli Lilly generated a RORI of 26 per cent and 24 per cent, ...

Semaglutide generics set to enter the Canadian market by 2026 after Novo Nordisk failed to maintain key patent | Speculation ...

The NHS Mounjaro rollout begins next week across the UK, and here are the side effects users need to be aware of ...

Eli Lilly's stock price has over-corrected following a downgrade in its outlook following the adjustment for acquisition ...

Novo Nordisk, the maker of Ozempic and Wegovy, is predicted to lose billions in profits due to a minor billing error in ...

A phased rollout of Mounjaro is set to begin across the UK next week as GP surgeries issue an urgent warning to patients.

They were designed to treat diabetes, then prescribed for weight loss, and now—as researchers are finding—they might hold the ...

WEIGHT loss jabs, including Mounjaro and Wegovy, have been linked to more than 100 deaths in the UK, new figures have revealed. But none of the fatalities are proven to have been caused directly ...

Big Pharma executives have not been shy about their desire for deals, but companies have been battling macro headwinds ...

Novo Nordisk A/S shares are staging a comeback after a tumultuous year for the maker of Ozempic and Wegovy. The stock is up ...

Obesity is a global health crisis with profound clinical and societal consequences, contributing to increased risks of chronic illness and related mortality.1 Despite being recognised as a disease by ...